protein

ANG

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ANG: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

263Connections
27Hypotheses
0Analyses
50Outgoing
50Incoming
2Experiments
0Debates

Summary

ANG is a protein involved in neurodegeneration research. Key relationships include: activates, associated with, therapeutic target. Associated with Als, Cancer, Cardiac. Connected to 149 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info
Gene SymbolANG
Full NameAngiogenin
AliasesGene profile: ANG
Chromosome14q11.2
Protein TypeProtein
Functionis a multifunctional protein that plays critical roles in both physiological and pathological processes within the nervous system.
Molecular Weight14 kDa
Amino Acids147 aa
Exons2
PathwaysNF-κB
UniProt IDSearch UniProt
GeneCardsANG
Human Protein AtlasANG
Associated DiseasesCardiac, Heart Failure, Hypertension, Inflammation, Neuroinflammation
InteractionsActin, AGING, AKT, ANXA2, APOE, APOPTOSIS
KG Connections263 knowledge graph edges
DatabasesGeneCardsNCBI GeneHPASTRING
🔮 Predicted Structure: ANG — AlphaFold SEARCH Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (5)

Knowledge base pages for this entity

Canonical Page

ANG — Angiogenin

gene · 2561 words

ANG Protein (Angiogenin)

protein · 2618 words

ANG Protein

protein · 2518 words

ANG Protein (Angiogenin)

protein · 909 words

BANG — BAG3 (Bcl-2-Associated Athanogene 3)

gene · 893 words

Pathway Diagram

graph TD
    ANG["ANG"]
    Als{"Als"}
    ANG -->|"inhibits"| Als
    Cardiovascular{"Cardiovascular"}
    ANG -->|"activates"| Cardiovascular
    Inflammation{"Inflammation"}
    ANG -->|"activates"| Inflammation
    Fibrosis{"Fibrosis"}
    ANG -->|"activates"| Fibrosis
    Cardiac{"Cardiac"}
    ANG -->|"activates"| Cardiac
    Ms{"Ms"}
    ANG -->|"activates"| Ms
    ANG -->|"activates"| Als
    Tumor{"Tumor"}
    ANG -->|"activates"| Tumor
    KCNK2["KCNK2"]
    ANG -->|"activates"| KCNK2
    ANG -->|"inhibits"| KCNK2
    NRP1["NRP1"]
    ANG -->|"activates"| NRP1
    APOE["APOE"]
    ANG -->|"associated with"| APOE
    PKC["PKC"]
    PKC -->|"inhibits"| ANG
    TRPA1["TRPA1"]
    TRPA1 -->|"regulates"| ANG
    MIRNAS["MIRNAS"]
    MIRNAS -->|"regulates"| ANG
    CAT["CAT"]
    CAT -->|"activates"| ANG
    ANXA2["ANXA2"]
    ANXA2 -->|"activates"| ANG
    TLR4["TLR4"]
    TLR4 -->|"activates"| ANG
    BCL2["BCL2"]
    BCL2 -->|"activates"| ANG
    style ANG fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (180)

TargetRelationTypeStr
Cardiacactivatesdisease0.85
Alsactivatesdisease0.85
Heart Failureassociated_withdisease0.75
Inflammationactivatesdisease0.75
Cardiovascularactivatesdisease0.75

Incoming (83)

SourceRelationTypeStr
TRPA1regulatesgene0.60
ANXA2activatesgene0.60
TLR4activatesgene0.60
BCL2activatesgene0.60
PI3Kactivatesgene0.60

Targeting Hypotheses (27)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Ganglioside Rebalancing Therapy 0.690 neurodegeneration Lipid raft composition changes in synapt
APOE ε4-driven microglial lipid handling as proximal driver 0.626 neurodegeneration Non-Neuronal Transcriptional Changes Pre
Cell-state stratification is required to resolve Non-Neurona 0.612 neurodegeneration Non-Neuronal Transcriptional Changes Pre
Microglial priming is primarily epigenetic, with metabolic c 0.609 neuroinflammation Do microglia actually switch between gly
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Non-Neuronal Transcriptional Changes Pre
Ganglioside-rich extracellular vesicles preserve alpha-synuc 0.582 neurodegeneration Which specific CSF molecular components
LYTL and JIP4-dependent lysosomal remodeling may show mutant 0.580 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
C1Q-Angiogenic Axis Promoting Plaque Neovascularization 0.530 neuroinflammation What are the specific molecular mechanis
Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Dow 0.517 neuroinflammation What causes IBA1 low/negative microglia
Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α 0.470 neurodegeneration What are the optimal oxygen pressure, du
Tau Conformational Change-Triggered Membrane Disruption 0.455 molecular-biology Can nanobodies achieve selective membran
GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ 0.454 lipidomics Lipid metabolism dysregulation in Alzhei
Parthenolide changes ADORA2A coupling efficiency through mem 0.435 neuropharmacology How does parthenolide specifically modul
APOE4 alters the accessible-cholesterol threshold sensed by 0.420 molecular-biology Does APOE4's reduced lipid-binding direc
APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside- 0.380 alzheimer Lipid metabolism dysregulation and membr
HSP90-CDC37 complex recognizes exposed hydrophobic clusters 0.380 protein-biochemistry Do chaperones selectively recognize path
tight-junction remodeling is the actionable driver in: Blood 0.362 neurodegeneration Blood-brain barrier permeability changes
Gap Junction Hemichannel Modulation for Controlled Mitochond 0.361 neurodegeneration Mitochondrial transfer between neurons a
endothelial transcytosis defines the therapeutic window for: 0.357 neurodegeneration Blood-brain barrier permeability changes
plasma GFAP separates causal from compensatory states in: Bl 0.346 neurodegeneration Blood-brain barrier permeability changes
protective chromatin remodeling defines the therapeutic wind 0.345 neurodegeneration Are DNA methylation changes in neurodege
age-linked CpG drift is the actionable driver in: Are DNA me 0.344 neurodegeneration Are DNA methylation changes in neurodege
age-linked CpG drift is the actionable driver in: Are age-re 0.344 neurodegeneration Are age-related DNA methylation changes
ATAC-seq accessibility separates causal from compensatory st 0.342 neurodegeneration Are DNA methylation changes in neurodege
ATAC-seq accessibility separates causal from compensatory st 0.327 neurodegeneration Are age-related DNA methylation changes
protective chromatin remodeling defines the therapeutic wind 0.326 neurodegeneration Are age-related DNA methylation changes
Ganglioside Rebalancing Therapy via ST3GAL5 Modulation 0.000 - Lipid metabolism dysregulation and membr

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Longitudinal dietary change analysis and ADRD risk over 10 years clinical Alzheimer's disease and relate 0.930 0.00 human patients proposed N/A
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $7,100,000

Related Papers (14)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Genetic variants in ganglioside synthesis enzymes associate with Alzheimer's dis [PMID:synthetic_29] Unknown Nat Genet 2024 0
CSF ganglioside ratios predict Alzheimer's disease progression and correlate wit [PMID:synthetic_27] Unknown JAMA Neurol 2023 0
Small-molecule modulation of ganglioside synthesis normalizes brain lipid compos [PMID:synthetic_26] Unknown Nat Neurosci 2023 0
Glycosphingolipid-Glycan Signatures of Acute Myeloid Leukemia Cell Lines Reflect [PMID:35168327] ["Wang D", "Zhang T", "Maduni\u0107 K", Journal of proteome research 2022 0
Brain ganglioside composition is dysregulated in Alzheimer's disease with GM1 de [PMID:synthetic_24] Unknown Ann Neurol 2022 0
GM1 enhances BDNF-TrkB signaling and neuroprotection via lipid raft organization [PMID:synthetic_28] Unknown Mol Psychiatry 2022 0
Ganglioside composition varies widely across brain regions and cell types [PMID:synthetic_32] Unknown J Lipid Res 2021 0
Exogenous GM1 administration improves cognition and reduces pathology in APP/PS1 [PMID:synthetic_25] Unknown Neurobiol Aging 2020 0
Exogenous GM1 shows limited CNS bioavailability in clinical trials for Parkinson [PMID:synthetic_30] Unknown Mov Disord 2019 0
Ganglioside synthesis inhibitors cause peripheral neuropathy in Gaucher disease [PMID:synthetic_31] Unknown Ann Neurol 2018 0
Dynamism in gene expression across multiple studies. [PMID:19920211] ["Morgan A", "Dudley J", "Deshpande T", Physiological genomics 2010 0
Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricu [PMID:16505173] ["Pilichou K", "Nava A", "Basso C", "Bef Circulation 2006 0
Epidermal growth factor receptor as a therapeutic target in human thyroid carcin [PMID:16822827] ["Mitsiades C", "Kotoula V", "Poulaki V" The Journal of clinical endocr 2006 0
Re: Use of an Amplatz Goose Neck Snare as a Target for Collateral Neck Vein Dial [PMID:11585895] Funaki B; Zaleski G X Journal of Vascular and Interv 2001 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning ANG in their description or question text

Ganglioside-rich extracellular vesicles preserve alpha-synuclein fibril conforma

Score: 0.582 · neurodegeneration · 2026-04-25

Membrane-derived cofactors in extracellular vesicles maintain polymorph fidelity and templating competence.

LYTL and JIP4-dependent lysosomal remodeling may show mutant-selective amplifica

Score: 0.580 · neurodegeneration · 2026-04-24

A more mechanistic but less translationally mature possibility is that G2019S does not strongly alter total phospho-Rab

C1Q-Angiogenic Axis Promoting Plaque Neovascularization

Score: 0.530 · neuroinflammation · 2026-04-21

## Mechanistic Overview C1Q-Angiogenic Axis Promoting Plaque Neovascularization starts from the claim that modulating C1

Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2

Score: 0.517 · neuroinflammation · 2026-04-21

## Mechanistic Overview Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2 starts from the

Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α to enhance VEGF-med

Score: 0.470 · neurodegeneration · 2026-04-25

This hypothesis claims HBOT at 1.5-2.0 ATA produces sub-lethal oxidative stress that paradoxically stabilizes HIF-1α des

Tau Conformational Change-Triggered Membrane Disruption

Score: 0.455 · molecular-biology · 2026-04-27

Nanobodies that recognize specific tau conformational epitopes and simultaneously possess membrane-disrupting activity c

GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization See

Score: 0.454 · lipidomics · 2026-04-25

GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization Seeds

Parthenolide changes ADORA2A coupling efficiency through membrane microdomain re

Score: 0.435 · neuropharmacology · 2026-04-25

The scaffold alters receptor signaling efficacy without strong orthosteric affinity by modifying redox-sensitive lipid n

APOE4 alters the accessible-cholesterol threshold sensed by SCAP through ER memb

Score: 0.420 · molecular-biology · 2026-04-24

A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives c

APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-mediated amyloid nuc

Score: 0.380 · alzheimer · 2026-04-27

In APOE4 carriers, the composition of astrocyte-secreted APOE-containing lipid particles becomes enriched in ganglioside

HSP90-CDC37 complex recognizes exposed hydrophobic clusters as amyloidogenic dan

Score: 0.380 · protein-biochemistry · 2026-04-27

The HSP90-CDC37 chaperone complex functions as a specialized surveillance system that recognizes amyloidogenic protein s

tight-junction remodeling is the actionable driver in: Blood-brain barrier perme

Score: 0.362 · neurodegeneration · 2026-04-26

The gap can be tested by treating tight-junction remodeling as an upstream driver rather than a passive correlate. If tr

Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange

Score: 0.361 · neurodegeneration · 2026-04-02

## Mechanistic Overview The hypothesis proposes that selective pharmacological modulation of pannexin-1 (Panx1) hemicha

endothelial transcytosis defines the therapeutic window for: Blood-brain barrier

Score: 0.357 · neurodegeneration · 2026-04-26

The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dos

plasma GFAP separates causal from compensatory states in: Blood-brain barrier pe

Score: 0.346 · neurodegeneration · 2026-04-26

A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. Th